[an error occurred while processing this directive] | [an error occurred while processing this directive]
Long-term follow-up of patients with early-stage diffuse large B-cell lymphoma of Waldeyer’s ring treated with intensity-modulated radiotherapy
Song Xue,Wu Lirong,Chen Zhenzhang,Jiang Ning,Wang Dejun,Zhao Lijun,Bian Xiuhua,He Xia
Department of Radiation Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Affiliated Cancer Hospital of Nanjng Medical University,Nanjing 210009,China
Abstract Objective To evaluate the treatment outcome, prognostic factors, radiation dose, and toxicities in patients with early-stage primary diffuse large B-cell lymphoma of Waldeyer’s ring (WR-DLBCL) treated with intensity-modulated radiotherapy (IMRT). Methods This study included 80 patients with a confirmed diagnosis of stage Ⅰ—Ⅱ primary WR-DLBCL who were admitted to our hospital from 2008 to 2015. Only 3 patients received radiotherapy alone, and the other patients received radiotherapy and chemotherapy. After chemotherapy, 24 patients achieved complete remission (CR), and 53 patients achieved partial remission (PR). IMRT was given to the primary lesion and cervical lymphatic drainage region. Survival analysis was performed using the Kaplan-Meier method and log-rank test. The Cox model was used for analysis of prognostic factors. The toxicities were scored using the RTOG criteria. Results The median follow-up was 64 months. The 5-year locoregional control (LRC), overall survival (OS), and progression-free survival (PFS) rates were 94%, 88%, and 84%, respectively. The dose-volume histogram showed that the maximum, mean, and minimum doses to primary gross tumor volume were 54.47 Gy, 52.27 Gy, and 38.83 Gy, respectively. Prognostic analysis showed that age>60 years and increased lactate dehydrogenase (LDH) were influencing factors for OS (P=0.009 and 0.002), and that aged>60 years, IPI ≥2, and increased LDH were influencing factors for PFS (P=0.001, 0.035, and 0.007). Among all patients, 12, 53, and 8 experienced grade 1-3 radiation-induced acute oral mucositis, respectively, and 16 and 13 experienced grade 1 and 2 xerostomia as the late toxicity, respectively. Conclusions For patients with early-stage primary WR-DLBCL, IMRT results in satisfactory OS, PFS, and LRC and has tolerable early or late radiation-induced toxicities.
Corresponding Authors:
He Xia,Email:Email:hexiabm@163.com
Cite this article:
Song Xue,Wu Lirong,Chen Zhenzhang et al. Long-term follow-up of patients with early-stage diffuse large B-cell lymphoma of Waldeyer’s ring treated with intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 904-908.
Song Xue,Wu Lirong,Chen Zhenzhang et al. Long-term follow-up of patients with early-stage diffuse large B-cell lymphoma of Waldeyer’s ring treated with intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 904-908.
[1] Tan L H.Lymphomas involving Waldeyer′s ring:placement,paradigms,peculiarities,pitfalls,patterns and postulates[J].Ann Acad Med Singapore,2004,33(4 Suppl):15-26. [2] 徐勇刚,李晔雄,王维虎,等.200例原发韦氏环弥漫大 B 细胞淋巴瘤的治疗及预后[J].中华放射肿瘤学杂志,2015(4):382-386. DOI:10.3760/j.issn.1004-4221.2015.04.009 Xu YG,Li YX,Wang WH,et al. Treatment and prognosis of 200 patients with primary diffuse diffuse B cell lymphoma of the ring[J],Chin J Radiat Oncol,2015(4):382-386. DOI:10.3760/j.issn.1004-4221.2015.04.009 [3] Xu YG,Qi S N,Wang S L,et al. Dosimetric and Clinical Outcomes With Intensity Modulated radiation therapy after chemotherapy for patients with early-stage diffuse large b-cell lymphoma of waldeyer ring[J].Int J Radiat Oncol Biol Phys,2016,96(2):379-386.DOI:10.1016/j.ijrobp.2016.05.023. [4] Qi SN,Li YX,Wang H,et al. Diffuse large B-cell lymphoma:clinical characterization and prognosis of Waldeyer ring versus lymph node presentation[J].Cancer,2009,115(21):4980-4989.DOI:10.1002/cncr.24557. [5] Wu RY,Li YX,Wang WH,et al. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma[J].Am J Clin Oncol,2014,37(1):41-46.DOI:10.1097/COC.0b013e318261084b. [6] Laskar S,Muckaden MA,Bahl G,et al. Primary non-Hodgkin′s lymphoma of the nasopharynx:prognostic factors and outcome of 113 Indian patients[J].Leuk Lymphoma,2006,47(10):2132-2139.DOI:10.1080/10428190600733531. [7] Bi XW,Li YX,Fang H,et al. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer′s ring:dosimetric analysis and clinical outcome[J].Int J Radiat Oncol Biol Phys,2013,87(5):1086-1093.DOI:10.1016/j.ijrobp.2013.08.040. [8] 汪华,李晔雄,王维虎,等.早期鼻腔和韦氏环NK/T细胞淋巴瘤IMRT的初步结果[J].中华放射肿瘤学杂志,2010,19(2):120-125.DOI:10.3760/cma.j.issn.1004-4221.2010.02.010. Wang H,Li YH,Wang WH,et al. Preliminary results of IMRT in early nasal cavity and NK/T ring cell lymphoma[J].Chin J Radiat Oncol,2010,19(2):120-125.DOI:10.3760/cma.j.issn.1004-4221.2010.02.010. [9] Kam MK,Leung SF,Zee B,et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients[J].J Clin Oncol,2007,25(31):4873-4879.DOI:10.1200/JCO.2007.11.5501. [10] Nutting CM,Morden JP,Harrington KJ,et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT):a phase 3 multicentre randomised controlled trial[J].Lancet Oncol,2011,12(2):127-136.DOI:10.1016/S1470-2045(10)70290-4. [11] Saleh-Ebrahimi L,Zwicker F,Muenter MW,et al. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer-a retrospective single center analysis[J].Radiat Oncol,2013,8:20.DOI:10.1186/1748-717X-8-20. [12] Wang H,Li YX,Wang WH,et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma[J].Int J Radiat Oncol Biol Phys,2012,82(3):1115-1121.DOI:10.1016/j.ijrobp.2011.02.039. [13] Xu LM,Li YX,Fang H,et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma[J].Int J Radiat Oncol Biol Phys,2013,85(5):1289-1295.DOI:10.1016/j.ijrobp.2012.10.037. [14] Bi XW,Li YX,Fang H,et al. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer′s ring:dosimetric analysis and clinical outcome[J].Int J Radiat Oncol Biol Phys,2013,87(5):1086-1093.DOI:10.1016/j.ijrobp.2013.08.040. [15] Kielbassa A M,Hinkelbein W,Hellwig E,et al. Radiation-related damage to dentition[J].Lancet Oncol,2006,7(4):326-335. [16] Goncalves LM,Palma-Dibb RG,Paula-Silva FW,et al. Radiation therapy alters microhardness and microstructure of enamel and dentin of permanent human teeth[J].J Dent,2014,42(8):986-992.DOI:10.1016/j.jdent.2014.05.011. [17] de Siqueira MT,Palma-Dibb RG,de Oliveira HF,et al. The effect of radiation therapy on the mechanical and morphological properties of the enamel and dentin of deciduous teeth—an in vitro study[J].Radiat Oncol,2014,9):30.DOI:10.1186/1748-717X-9-30. [18] Reed R,Xu C,Liu Y,et al. Radiotherapy effect on nano-mechanical properties and chemical composition of enamel and dentine[J].Arch Oral Biol,2015,60(5):690-697.DOI:10.1016/j.archoralbio.2015.02.020. [19] 罗加林,刘鲁迎,吴润叶,等.130例鼻腔和韦氏环NK/T细胞淋巴瘤放化疗预后分析[J].中华放射肿瘤学杂志,2013,22(3):180-184.DOI:10.3760/cma.j.issn.1004-4221.2013.03.002. Luo JL,Liu LY,Wu RY,et al. Prognostic analysis of radiotherapy and chemotherapy in 130 cases of nasal cavity and NK/T ring cell lymphoma[J].Chin J Radiat Oncol,2013,22(3):180-184. DOI:10.3760/cma.j.issn.1004-4221.2013.03.002. [20] Santos RC,Dias RS,Giordani AJ,et al.Mucositis in head and neck cancer patients undergoing radiochemotherapy[J].Rev Esc Enferm USP,2011,45(6):1338-1344. [21] 赵路军,李晔雄,袁智勇,等.原发于舌根NHL临床特点及预后[J].中华放射肿瘤学杂志,2003,12(1):21-24. Zhao LJ,Li YX,Yuan ZY,et al. Primary clinical characteristics and prognosis of tongue NHL[J].Chin J Radiat Oncol,2003,12(1):21-24. [22] Rosenwald A,Wright G,Chan WC,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma[J].N Engl J Med,2002,346(25):1937-1947. [23] 余正平,丁家华,陈宝安,等.影响弥漫大B细胞淋巴瘤预后的主要危险因素分析[J].中华血液学杂志,2011,32(12):830-835.DOI:10.3760/cma.j.issn.0253-2727.2011.12.006. Yu ZP,Ding JH,Chen BA,et al. Analysis of the main risk factors for prognosis of diffuse large B cell lymphoma[J].Chin J Hematol,2011,32(12):830-835.DOI:10.3760/cma.j.issn.0253-2727.2011.12.006.
2017, Vol. 26 
